8432 results for "canc*"

in 13.64 milliseconds.

• SCANDARE HNSCC

  Prospective biobanking study in SCANDARE HNSCC (Head and Neck Squamous Cell Carcinoma) patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response.

  Study EGAS50000001158

• DAC for RNAseq data associated with transcriptomic profiling of ER alpha positive breast cancer patients before and after endocrine therapy

  This Data Access Committee (DAC) oversees access to RNAseq data collected as part of a study focussed on exploring transcriptomic profiles of ER alpha positive breast cancer patients who were treated with aromatase inhibitors for up to three months before surgical removal of the primary tumor. Sampling was performed at diagnosis and at surgery, and RNA-seq was performed. The DAC ensures that data access requests comply with the study's ethical and legal frameworks and that data is shared for non-commercial, academic research purposes under controlled access to protect participant privacy.

  Dac EGAC50000000499

• Transcriptomics profiling of paired pre- and post- neo-adjuvant endocrine therapy of ERa positive breast cancers

  Patients were treated with aromatase inhibitors for up to three months before surgical removal of the primary tumor. Sampling was performed at diagnosis and at surgery, and RNA-seq was performed.

  Study EGAS50000000832

• Colossus Project Single-nuclei RNA sequencing

  Single-nuclei RNA sequencing of human colorectal cancer samples. Nuclei were isolated on ice, followed by single-nuclei RNA-sequencing library preparation using the Chromium Single Cell 3’ reagent kit v3.1 (10x Genomics, Pleasanton, CA) Fastq files, N=18

  Dataset EGAD50000003002

• Colossus Project Whole exome sequencing

  Whole exome sequencing of colorectal cancer samples from stage 2/3 human patients. Whole-genome DNA libraries were prepared with the KAPA HyperPlus kit (Roche, Cape Town, South Africa), and exome fragments were captured using the SureSelect Human All Exon V7 kit (Agilent, Hangzhou, China) Fastq files, N=88

  Dataset EGAD50000003003

• Colossus Project Bulk Tumor RNA sequencing

  Bulk RNA sequencing of colorectal cancer samples from stage 2/3 human patients. RNA extraction using Qiagen RNeasy FFPE Extraction kit (Qiagen, UK), followed by RNA sequencing library generation with the QuantSeq 3' mRNA-Seq Library Prep Kit (FWD) (Illumina, USA). Fastq files, N=295

  Dataset EGAD50000003004

• Colossus Project Whole Genome Sequencing

  Low-coverage whole genome sequencing of colorectal cancer samples from stage 2/3 human patients. Tumor DNA from biopsies was extracted using the QIAamp circulating nucleic acid kit (Qiagen, UK), followed by generation of shot-gun whole genome libraries using the KAPA library preparation kit (KAPA Biosystems). Fastq files, N=295

  Dataset EGAD50000003005

• Expansion and cytotoxicity of mucosal T cells in enterocolitis associated with BCMA CAR-T cell therapy

  This study investigates immune effector cell enterocolitis (IEC-EC) associated with ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory multiple myeloma. IEC-EC was characterized by infiltration and expansion of clonal CAR-positive cytotoxic T-cell populations within the gastrointestinal tract. Molecular analyses were performed to characterize CAR T-cell clonality, persistence, vector integration, and genomic alterations associated with this complication. This dataset contains whole-genome sequencing (WGS) and whole-exome sequencing (WES) FASTQ files generated as part of the study and associated with the corresponding manuscript.

  Study EGAS50000002146

• Circulating tumour DNA in oligoprogressing metastatic castration-resistant prostate cancer treated with stereotactic body radiotherapy in the TRAP trial

  The TRAP trial (NCT03644303) reported that stereotactic body radiotherapy (SBRT) of up to two imaging-visible metastases in prostate cancer patients showing disease progression whilst continuing an androgen receptor pathway inhibitor (ARPI) improved outcomes. It is possible that the benefit from treatment is heterogeneous and patients with progressing sub-clinical metastases, not detected by imaging, derived no benefit from this intervention. The goal of this study was to determine if ctDNA levels detected before SBRT associates with worse outcome.

  Study EGAS50000002152

• Breast Cancer Atlas Research Consortium (BCARC)

  The Breast Cancer Atlas Research Consortium (BCARC) is an international translational research programme building a multi-modal atlas of breast cancer across subtypes, disease progression states, and treatment phases. Founding investigators span the Swarbrick Laboratory (Garvan Institute of Medical Research, Sydney), the Perou Laboratory (University of North Carolina at Chapel Hill), the Grimmond Laboratory (University of Melbourne Centre for Cancer Research), the Al'Khafaji Laboratory (Broad Institute of MIT and Harvard), and the Lundeberg Laboratory (KTH Royal Institute of Technology, Stockholm). Samples are drawn from primary and metastatic breast tumours together with matched adjacent tissues and where available, blood samples. All samples derive from participants consented under Garvan-approved research protocols. Access is controlled and governed by the BCARC data access agreement; requests are reviewed by the Data Access Committee named in the associated policy record

  Study EGAS00001008520